



800 NE Oregon Street, Suite 640 Portland, OR 97232 Voice: 971-673-0490

Oregon Psilocybin Advisory Board

Date: April 28, 2021

Time: 1:00 pm – 4:00 pm

Location: Zoom.gov Meeting

Board Members Present: Dr. Tom Jeanne, Barbara Hansen, Dr. Ali Hamade, Dr. Sarah Present, Kevin Fitts, Dr. Kim Golletz, Todd Korthuis, Dr. Mason Marks, Dr. Jessie Uehling, Dr. Atheir Abbas, David Hart, Nathan Rix, Tom Eckert, Dr. Angela Carter, Stephanie Barrs, Dr. Rachel Knox

Oregon DOJ Staff: Shannon O'Fallon,

OHA staff: André Ourso, Nic Riley

Welcome and Call to order (André Ourso)

Approval of March 31 Meeting Minutes March 31, 2021 meeting minutes were approved without any edits or objections

DOJ Guidance on Board Communications (9:32 on audio)

Summary: Shannon O'Fallon gave a presentation on Public Meetings Law and Public Records law, including the laws that govern subcommittee activities and communications between board members.

Subcommittee Reports and Discussions (1:01:39 on audio)

<u>Training Subcommittee (Tom Eckert, Angela Carter, Kim Golletz, Stephanie Barss)</u>
Tom Eckert reported on the Training subcommittee's activities. The subcommittee met for the first time on April 23. The group is working to develop recommendations for

independent training programs that will include guidance on curriculum development and intends to provide those recommendations to the Board this summer.

Tom Eckert made a motion to approve Angela Carter to serve as co-chair of the Training Subcommittee. André Ourso seconded, and the motion was approved without objection.

Research Subcommittee (Todd Korthuis, Atheir Abbas, Tom Jeanne, Ali Hamade, Jessie Uehling, Angela Carter)

Todd Korthuis reported on the Research Subcommittee's activities. The subcommittee met for the first time on April 14d and discussed on the parameters of the evidence review. The group intends to begin circulating a draft of their compilation by the end of May, with the final document due on June 30.

Todd shared the subcommittee's initial draft list of nine key questions, using the term "psilocybin-assisted therapy":

- What are the benefits of psilocybin-assisted therapy seeking treatment for specific conditions?
- What are the benefits in healthy people who use psilocybin to improve wellness or promote spiritual growth?
- How do those benefits differ by population subgroup?
- How do different dosing strategies effect those benefits?
- What are the tools that providers can use to identify individuals who might benefit from psilocybin-assisted therapy?
- What are the potential risks of psilocybin-assisted therapy?
- What are the relative benefits and harms of different psilocybin sources?
- What are the best practices for psilocybin production?
- What are the best practices for dose control?

Todd Korthuis asked Board Members for their comments, and the board decided to vote on the precise wording of those questions at the next meeting.

Todd Korthuis asked the Board to approve Dr. Chris Stauffer to serve as a member of the Research Subcommittee. André Ourso made a motion to approve the nomination. Atheir Abbas seconded, and Dr. Stauffer's membership on the Research Subcommittee was approved.

Rachel Knox asked the Board to approve Dr. Del Potter to serve as a member of the Research Subcommittee. The Board decided to table that discussion, pending more information and a conflict of interest declaration from Dr. Potter.

3:00 Break

Discussion - Equity Subcommittee (2:04:54 on audio)

Dr. Rachel Knox and Dr. Angela Carter are the co-chairs of the subcommittee. They have developed a list of potential subcommittee members and will submit that list for the Board's approval at May's meeting.

<u>Discussion – Additional Subcommittees</u>

Summary: The Board approved the immediate formation of two additional subcommittees.

Licensing

Barb Hansen made a motion, and Mason Marks seconded the formation of a Licensing Subcommittee.

Jessie Uehling made a motion, and Atheir Abbas seconded the approval of Mason Marks as the Licensing Subcommittee chairperson.

Both motions passed without objection.

<u>Products</u>

Sarah Present made a motion, and Mason Marks seconded the formation of a Products Subcommittee.

Tom Eckert made a motion, and Mason Marks seconded the approval of Jessie Uehling as the Products Subcommittee chairperson.

Both motions passed without objection.

Chair and Vice-Chair Nominations

Jessie Uehling made a motion, and Tom Eckert seconded the dedication of the rest of today's meeting time to the appointment of a Board Chair and Vice chair.

Summary: The Board decided to elect a Chairperson and two Vice-Chairs.

Tom Eckert volunteered to serve as Chairperson. Jessie Uehling made a motion, and Mason Marks seconded the nomination of Tom Eckert to serve as Chairperson.

Dr. Rachel Knox nominated Kim Gullets, Atheir Abbas and Mason Marks to serve as Vice-Chairs.

Kim Golletz and Mason Marks both declined their nominations.

Jessie Uehling nominated Angela Carter to serve as Vice-Chair. Rachel Knox seconded the nomination.

Summary: Tom Eckert will be the Board Chairperson, Atheir Abbas and Angela Carter will serve as Vice-Chairs.

Next Psilocybin Advisory Board Meeting: May 26, 2021 1pm – 4pm Zoom Meeting